NYSE:NVRO

Nevro Competitors

$162.20
+1.14 (+0.71 %)
(As of 04/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$160.55
Now: $162.20
$167.02
50-Day Range
$132.81
MA: $146.12
$168.11
52-Week Range
$109.30
Now: $162.20
$188.14
Volume2.85 million shs
Average Volume471,445 shs
Market Capitalization$5.63 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.02

Competitors

Nevro (NYSE:NVRO) Vs. TFX, NVCR, PODD, ABMD, PEN, and HRC

Should you be buying NVRO stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to Nevro, including Teleflex (TFX), NovoCure (NVCR), Insulet (PODD), Abiomed (ABMD), Penumbra (PEN), and Hill-Rom (HRC).

Nevro (NYSE:NVRO) and Teleflex (NYSE:TFX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.

Valuation & Earnings

This table compares Nevro and Teleflex's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nevro$390.26 million14.42$-103,690,000.00($3.37)-48.13
Teleflex$2.60 billion7.91$461.47 million$11.1539.40

Teleflex has higher revenue and earnings than Nevro. Nevro is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Nevro has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, Teleflex has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500.

Profitability

This table compares Nevro and Teleflex's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nevro-24.46%-30.25%-14.57%
Teleflex14.66%16.33%7.66%

Insider & Institutional Ownership

89.8% of Teleflex shares are held by institutional investors. 7.6% of Nevro shares are held by company insiders. Comparatively, 2.2% of Teleflex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Nevro and Teleflex, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nevro031102.79
Teleflex00813.11

Nevro presently has a consensus price target of $181.3846, indicating a potential upside of 11.83%. Teleflex has a consensus price target of $453.4444, indicating a potential upside of 3.21%. Given Nevro's higher probable upside, equities analysts clearly believe Nevro is more favorable than Teleflex.

Summary

Teleflex beats Nevro on 11 of the 15 factors compared between the two stocks.

Nevro (NYSE:NVRO) and NovoCure (NASDAQ:NVCR) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings.

Valuation and Earnings

This table compares Nevro and NovoCure's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nevro$390.26 million14.42$-103,690,000.00($3.37)-48.13
NovoCure$351.32 million58.07$-7,230,000.00($0.07)-2,845.71

NovoCure has lower revenue, but higher earnings than Nevro. NovoCure is trading at a lower price-to-earnings ratio than Nevro, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Nevro has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, NovoCure has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500.

Profitability

This table compares Nevro and NovoCure's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nevro-24.46%-30.25%-14.57%
NovoCure4.26%7.40%3.94%

Insider & Institutional Ownership

71.1% of NovoCure shares are held by institutional investors. 7.6% of Nevro shares are held by insiders. Comparatively, 5.1% of NovoCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Nevro and NovoCure, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nevro031102.79
NovoCure14402.33

Nevro currently has a consensus price target of $181.3846, indicating a potential upside of 11.83%. NovoCure has a consensus price target of $170.8889, indicating a potential downside of 14.21%. Given Nevro's stronger consensus rating and higher probable upside, analysts clearly believe Nevro is more favorable than NovoCure.

Summary

NovoCure beats Nevro on 9 of the 14 factors compared between the two stocks.

Nevro (NYSE:NVRO) and Insulet (NASDAQ:PODD) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings.

Valuation and Earnings

This table compares Nevro and Insulet's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nevro$390.26 million14.42$-103,690,000.00($3.37)-48.13
Insulet$738.20 million25.44$11.60 million$0.191,492.84

Insulet has higher revenue and earnings than Nevro. Nevro is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Nevro has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500. Comparatively, Insulet has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500.

Profitability

This table compares Nevro and Insulet's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nevro-24.46%-30.25%-14.57%
Insulet3.33%8.94%2.07%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Nevro and Insulet, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nevro031102.79
Insulet19702.35

Nevro currently has a consensus price target of $181.3846, indicating a potential upside of 11.83%. Insulet has a consensus price target of $254.2353, indicating a potential downside of 10.37%. Given Nevro's stronger consensus rating and higher probable upside, analysts clearly believe Nevro is more favorable than Insulet.

Summary

Insulet beats Nevro on 8 of the 12 factors compared between the two stocks.

Nevro (NYSE:NVRO) and Abiomed (NASDAQ:ABMD) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings.

Volatility and Risk

Nevro has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Abiomed has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.

Profitability

This table compares Nevro and Abiomed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nevro-24.46%-30.25%-14.57%
Abiomed25.89%15.34%13.51%

Insider & Institutional Ownership

94.0% of Abiomed shares are held by institutional investors. 7.6% of Nevro shares are held by insiders. Comparatively, 3.4% of Abiomed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Nevro and Abiomed, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nevro031102.79
Abiomed12202.20

Nevro currently has a consensus price target of $181.3846, indicating a potential upside of 11.83%. Abiomed has a consensus price target of $348.3333, indicating a potential upside of 1.44%. Given Nevro's stronger consensus rating and higher probable upside, analysts clearly believe Nevro is more favorable than Abiomed.

Valuation and Earnings

This table compares Nevro and Abiomed's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nevro$390.26 million14.42$-103,690,000.00($3.37)-48.13
Abiomed$840.88 million18.47$203.01 million$4.7472.45

Abiomed has higher revenue and earnings than Nevro. Nevro is trading at a lower price-to-earnings ratio than Abiomed, indicating that it is currently the more affordable of the two stocks.

Summary

Abiomed beats Nevro on 10 of the 14 factors compared between the two stocks.

Nevro (NYSE:NVRO) and Penumbra (NYSE:PEN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Risk & Volatility

Nevro has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Nevro and Penumbra, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nevro031102.79
Penumbra02402.67

Nevro currently has a consensus target price of $181.3846, suggesting a potential upside of 11.83%. Penumbra has a consensus target price of $279.00, suggesting a potential downside of 2.99%. Given Nevro's stronger consensus rating and higher probable upside, analysts clearly believe Nevro is more favorable than Penumbra.

Valuation and Earnings

This table compares Nevro and Penumbra's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nevro$390.26 million14.42$-103,690,000.00($3.37)-48.13
Penumbra$547.41 million19.15$48.46 million$0.98293.47

Penumbra has higher revenue and earnings than Nevro. Nevro is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

88.2% of Penumbra shares are owned by institutional investors. 7.6% of Nevro shares are owned by company insiders. Comparatively, 8.9% of Penumbra shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Nevro and Penumbra's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nevro-24.46%-30.25%-14.57%
Penumbra-1.79%-0.12%-0.09%

Summary

Penumbra beats Nevro on 9 of the 14 factors compared between the two stocks.

Nevro (NYSE:NVRO) and Hill-Rom (NYSE:HRC) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Profitability

This table compares Nevro and Hill-Rom's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nevro-24.46%-30.25%-14.57%
Hill-Rom7.74%22.71%8.01%

Risk & Volatility

Nevro has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. Comparatively, Hill-Rom has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500.

Valuation and Earnings

This table compares Nevro and Hill-Rom's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nevro$390.26 million14.42$-103,690,000.00($3.37)-48.13
Hill-Rom$2.88 billion2.63$223 million$5.5320.65

Hill-Rom has higher revenue and earnings than Nevro. Nevro is trading at a lower price-to-earnings ratio than Hill-Rom, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

83.8% of Hill-Rom shares are owned by institutional investors. 7.6% of Nevro shares are owned by company insiders. Comparatively, 0.7% of Hill-Rom shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and price targets for Nevro and Hill-Rom, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nevro031102.79
Hill-Rom01502.83

Nevro currently has a consensus target price of $181.3846, suggesting a potential upside of 11.83%. Hill-Rom has a consensus target price of $120.3333, suggesting a potential upside of 5.38%. Given Nevro's higher probable upside, analysts clearly believe Nevro is more favorable than Hill-Rom.

Summary

Hill-Rom beats Nevro on 9 of the 14 factors compared between the two stocks.


Nevro Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Teleflex logo
TFX
Teleflex
1.8$439.35+0.2%$20.54 billion$2.60 billion56.54Upcoming Earnings
Decrease in Short Interest
Analyst Revision
NovoCure logo
NVCR
NovoCure
1.7$199.20+0.7%$20.40 billion$351.32 million1,048.48Upcoming Earnings
Analyst Report
Analyst Revision
Insulet logo
PODD
Insulet
1.4$283.64+0.5%$18.78 billion$738.20 million644.65Gap Down
Abiomed logo
ABMD
Abiomed
1.4$343.40+0.2%$15.53 billion$840.88 million75.47Upcoming Earnings
News Coverage
Penumbra logo
PEN
Penumbra
1.5$287.60+1.3%$10.48 billion$547.41 million-1,065.19
Hill-Rom logo
HRC
Hill-Rom
1.8$114.19+0.7%$7.58 billion$2.88 billion34.39Increase in Short Interest
News Coverage
Globus Medical logo
GMED
Globus Medical
1.4$71.01+0.2%$7.09 billion$785.37 million77.18Analyst Revision
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$74.38+0.0%$6.29 billion$1.52 billion111.01Upcoming Earnings
Insider Selling
News Coverage
Inspire Medical Systems logo
INSP
Inspire Medical Systems
1.2$228.13+0.6%$6.20 billion$82.05 million-98.33
Tandem Diabetes Care logo
TNDM
Tandem Diabetes Care
1.4$93.62+0.7%$5.86 billion$362.30 million-115.58
ShockWave Medical logo
SWAV
ShockWave Medical
1.2$158.31+3.1%$5.52 billion$42.93 million-78.37Analyst Report
Insider Selling
News Coverage
Inari Medical logo
NARI
Inari Medical
1.1$105.78+0.1%$5.24 billionN/A0.00Insider Selling
ICU Medical logo
ICUI
ICU Medical
1.5$213.78+0.9%$4.53 billion$1.27 billion56.56News Coverage
Glaukos logo
GKOS
Glaukos
0.9$91.75+1.3%$4.20 billion$236.98 million-55.61
Cantel Medical logo
CMD
Cantel Medical
1.3$88.09+0.1%$3.72 billion$1.02 billion104.87
NuVasive logo
NUVA
NuVasive
1.1$69.55+0.1%$3.57 billion$1.17 billion-316.14Analyst Report
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.5$62.17+1.6%$3.46 billion$994.85 million-117.30Upcoming Earnings
News Coverage
Haemonetics logo
HAE
Haemonetics
2.1$67.70+2.8%$3.44 billion$988.48 million32.71Analyst Report
Unusual Options Activity
News Coverage
AtriCure logo
ATRC
AtriCure
1.3$70.02+0.2%$3.19 billion$230.81 million-60.89Upcoming Earnings
Axonics Modulation Technologies logo
AXNX
Axonics Modulation Technologies
1.3$61.52+0.7%$2.55 billion$13.82 million-31.39Insider Selling
News Coverage
iRhythm Technologies logo
IRTC
iRhythm Technologies
1.5$82.72+1.8%$2.41 billion$214.55 million-43.31Analyst Report
Silk Road Medical logo
SILK
Silk Road Medical
0.9$57.77+2.1%$1.99 billion$63.35 million-47.35
Inovio Pharmaceuticals logo
INO
Inovio Pharmaceuticals
1.4$9.13+0.3%$1.90 billion$4.11 million-6.71Insider Selling
GenMark Diagnostics logo
GNMK
GenMark Diagnostics
1.5$24.04+0.0%$1.76 billion$88.02 million-58.63
Luminex logo
LMNX
Luminex
1.5$36.71+0.0%$1.74 billion$334.64 million94.13Analyst Report
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.5$40.69+1.2%$1.62 billion$236.54 million-61.65
Alphatec logo
ATEC
Alphatec
0.8$16.30+0.6%$1.55 billion$113.43 million-14.82
Pulmonx logo
LUNG
Pulmonx
1.4$43.00+2.3%$1.53 billion$32.60 million0.00Insider Selling
Atrion logo
ATRI
Atrion
1.1$662.27+1.3%$1.21 billion$155.07 million37.31
MiMedx Group logo
MDXG
MiMedx Group
1.7$10.64+1.3%$1.18 billion$299.26 million-11.32News Coverage
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.2$58.91+3.6%$1.16 billion$189.49 million-130.91News Coverage
SI-BONE logo
SIBN
SI-BONE
1.2$34.86+0.2%$1.14 billion$67.30 million-21.79Analyst Report
News Coverage
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.9$53.55+0.8%$1.10 billion$117.23 million57.58Upcoming Earnings
News Coverage
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.3$54.00+2.0%$1.06 billion$72.55 million-37.50Analyst Report
News Coverage
Cerus logo
CERS
Cerus
1.7$6.03+0.5%$1.01 billion$74.65 million-15.46
AngioDynamics logo
ANGO
AngioDynamics
1.4$24.16+0.7%$921.39 million$264.16 million-5.40
CryoLife logo
CRY
CryoLife
1.8$22.69+0.9%$895.85 million$276.22 million-59.71Upcoming Earnings
News Coverage
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$44.64+1.4%$871.02 million$459.95 million37.20News Coverage
Surmodics logo
SRDX
Surmodics
1.3$58.73+0.2%$807.89 million$94.86 million734.13Upcoming Earnings
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$9.84+0.5%$707.95 million$154.60 million-42.78News Coverage
Intersect ENT logo
XENT
Intersect ENT
1.5$20.61+1.5%$680.46 million$109.14 million-10.79Analyst Upgrade
Antares Pharma logo
ATRS
Antares Pharma
1.8$3.95+0.8%$664.24 million$123.86 million65.84Analyst Downgrade
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$42.82+2.7%$613.61 million$114.51 million-91.11
SeaSpine logo
SPNE
SeaSpine
1.3$21.20+0.9%$592.65 million$159.08 million-12.69
Vapotherm logo
VAPO
Vapotherm
1.5$21.71+0.8%$560.27 million$48.10 million-10.34News Coverage
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.5$20.77+1.3%$548.29 millionN/A-9.15News Coverage
Accuray logo
ARAY
Accuray
2.3$5.26+2.9%$488.64 million$382.93 million37.57Upcoming Earnings
iCAD logo
ICAD
iCAD
1.7$17.85+0.3%$444.79 million$31.34 million-18.79Upcoming Earnings
Analyst Upgrade
Gap Down
AVITA Medical logo
RCEL
AVITA Medical
1.4$19.89+0.1%$430.20 million$14.26 million-9.61Analyst Downgrade
Acutus Medical logo
AFIB
Acutus Medical
1.3$14.15+4.5%$397.54 million$2.84 million0.00
This page was last updated on 4/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.